1. Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens 
Sam Afkhami, Yushi Yao, Zhou Xing 
Molecular Therapy - Methods & Clinical Development 
Volume 3, (January 2016)
DOI: /mtm
Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

2. Figure 1
Organization and function(s) of the adenoviral genome. The organization, orientation, and broad function(s) of the adenoviral transcriptional units are depicted. Knowledge of the entire adenoviral genome is critical in the downstream construction of adenoviral-vectored vaccines.
Molecular Therapy - Methods & Clinical Development 2016 3, DOI: ( /mtm )
Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

3. Figure 2
Development of adenoviral-vectored vaccines through homologous recombination. The most commonly used strategy in the generation of E1-deleted human adenoviral vectors (homologous recombination in a viral packaging cell line) is depicted.
Molecular Therapy - Methods & Clinical Development 2016 3, DOI: ( /mtm )
Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

4. Figure 3
Development of adenoviral-vectored vaccines through a direct-cloning strategy. Generation of adenoviral vectors through direct in vitro molecular cloning of the entire adenovirus is depicted. This represents an alternative strategy in the generation of adenoviral vectors, bypassing the need for homologous recombination.
Molecular Therapy - Methods & Clinical Development 2016 3, DOI: ( /mtm )
Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions